Altimmune, a clinical-stage biopharmaceutical developing pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity, could run on the obesity drug story.
For one, it may have the same fiery potential we’ve seen with other obesity drug stocks.
That’s because data from a 48-week trial showed that about 74.5% of weight loss was linked to fat tissue. About 25.5% was linked to lean mass, which may give it a leg up against the competition. “We believe that pemvidutide has the potential to distinguish itself broadly from other therapies for the treatment of obesity,” ALT CEO Vipin Garg added.
After all, preservation of lean mass with weight loss is critical, says the company. If a person loses too much lean mass during weight loss, it can lead to severe medical outcomes, such as musculoskeletal issues and bone fractures, as also highlighted by the company.
That alone could be a major game-changer for a company like Altimmune.
Goldman Sachs also just raised its obesity market estimate to $130 billion from $100 billion.